BRIEF — Xtandi tablets launched in Japan for castration-resistant prostate cancer

Astellas Pharma has launched 40 mg and 80mg Xtandi (enzalutamide) tablets in Japan for the treatment of castration-resistant prostate cancer.

This launch adds additional dosage forms to the previously available 40 mg Xtandi capsules and adds an option that is smaller in size and, in the case of the 80mg tablets, the number of doses taken each time will be reduced.

Xtandi, an oral androgen receptor signaling inhibitor, is jointly commercialized by Astellas and Pfizer in the USA.